Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release  by Ilyinskii, Petr O. et al.
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Augmentation  of immunogenicity  can be  achieved  by  particulate  delivery  of an  antigen  and  by its
co-administration  with  an  adjuvant.  However,  many  adjuvants  initiate  strong  systemic  inﬂammatory
reactions  in vivo,  leading  to potential  adverse  events  and  safety  concerns.  We  have  developed  a  synthetic
vaccine  particle  (SVP)  technology  that  enables  co-encapsulation  of  antigen  with  potent  adjuvants.  We
demonstrate  that  co-delivery  of an  antigen  with  a TLR7/8  or TLR9  agonist  in  synthetic  polymer  nanopar-
ticles  results  in  a strong  augmentation  of  humoral  and  cellular  immune  responses  with  minimal  systemic
production  of inﬂammatory  cytokines.  In contrast,  antigen  encapsulated  into  nanoparticles  and  admixed
with  free  TLR7/8  agonist  leads  to  lower  immunogenicity  and  rapid  induction  of high  levels  of inﬂam-
matory  cytokines  in the  serum  (e.g.,  TNF-  and  IL-6  levels  are  50- to 200-fold  higher  upon  injection  of
free  resiquimod  (R848)  than  of  nanoparticle-encapsulated  R848).  Conversely,  local  immune  stimulation
as  evidenced  by  cellular  inﬁltration  of  draining  lymph  nodes  and  by  intranodal  cytokine  production  was
more  pronounced  and  persisted  longer  when  SVP-encapsulated  TLR  agonists  were  used.  The  strong  local
immune  activation  achieved  using  a modular  self-assembling  nanoparticle  platform  markedly  enhanced
immunogenicity  and  was  equally  effective  whether  antigen  and  adjuvant  were  co-encapsulated  in  a
single  nanoparticle  formulation  or co-delivered  in  two  separate  nanoparticles.  Moreover,  particle  encap-
sulation  enabled  the  utilization  of  CpG  oligonucleotides  with  the natural  phosphodiester  backbone,  which
are  otherwise  rapidly  hydrolyzed  by  nucleases  in  vivo.  The  use  of  SVP  may  enable  clinical  use  of potent
TLR  agonists  as vaccine  adjuvants  for indications  where  cellular  immunity  or  robust  humoral  responses
are  required.
©  2014 The  Authors.  Published  by Elsevier  Ltd.  
Abbreviations: DC, dendritic cell; LN, lymph node; ODN, oligonucleotide; PAMP, pathogen-associated molecular pattern; PAP, prostatic acid phosphatase;
O, phosphodiester; PS, phosphorothioate; PRR, pattern recognition receptor; SVP, synth
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. Introduction
Vaccine adjuvants augment the immune response by pro-
oting more effective antigen processing, presentation, and/or
elivery [1]. Aluminum salts (alum) were ﬁrst introduced as vac-
ine adjuvants over 80 years ago when little was known about
he cellular or molecular mechanisms of the immune response
2], yet alum remains the most widely used adjuvant today due
o its demonstrated safety proﬁle and effectiveness when com-
ined with many clinically important antigens [3,4]. However, alum
s not sufﬁciently potent to attain protective responses to poorly
mmunogenic entities [5–9]. Additionally, alum preferentially pro-
otes Th2 type responses [2–4,10], which may  exacerbate adverse
nﬂammatory reactions to some respiratory pathogens, such as the
espiratory syncytial virus (RSV) [11], and does not efﬁciently aug-
ent cytotoxic T cell responses, which are necessary to provide
rotective immunity against many viral antigens or therapeutic
mmunity against cancer-related antigens [12]. One of the main
hallenges of current vaccine development is to advance the clin-
cal application of newly developed and potent adjuvants without
ompromising safety [12,13].
Novel adjuvant candidates have emerged from the discovery
f pattern recognition receptors (PRR) that recognize pathogen-
ssociated molecular patterns (PAMP) and damage-associated
olecular patterns (DAMP) [14–17]. Research on PRRs has pro-
ided insight into how the innate system activates and modulates
he adaptive immune system [16]. Microbial PAMPs, such as
ipopolysaccharides, single-stranded RNA, and bacterial DNA
otifs, bind to a family of PRRs called Toll-like receptors (TLR) on
nnate immune cells and stimulate antigen processing and pre-
entation [16–18]. TLRs are widely expressed on dendritic cells
DC) and other professional APCs such as macrophages and B
ells. While some TLRs are expressed on the cell surface and act
s sensors for extracellular PAMPs (e.g., lipopolysaccharides), a
ubset of TLR molecules (TLR3, 7, 8 and 9) are expressed on endo-
omal membranes and bind nucleic acid-derived molecules, such as
ingle-stranded RNA of viral origin for TLR7 and 8 [19–24] and bac-
erial unmethylated DNA oligonucleotides (ODNs) containing CpG
otifs (CpG ODNs) for TLR9 [14,25–28]. TLR ligands of natural and
ynthetic origin are potent inducers of innate immune responses
nd have been shown to effectively stimulate the transition from
n innate immune response to an adaptive immune response. As
uch, TLR agonists have been evaluated as potential adjuvants in a
ariety of applications [4].
To date, only one PRR ligand, 3-O-desacyl-4′-monophosphoryl
ipid A (MPL), a TLR4 agonist, has been included as an adjuvant
n a FDA- or EMA-licensed vaccine. MPL  adsorbed onto alum is
tilized in the HPV vaccine Cervarix, licensed in the U.S. and
urope [29], and the hepatitis B vaccine Fendrix, licensed in Europe
30]. Imiquimod, a topically administered TLR7 agonist, has been
pproved for treatment of genital warts, actinic keratosis, and basal
ell carcinoma [31]. Other TLR agonists, such as poly(I:C) (TLR3),
midazoquinolines other than imiquimod (TLR7, 8, or 7/8), and CpG
DNs (TLR9), have failed thus far to enter clinical practice as par-
nteral adjuvants despite a multitude of promising data obtained
n preclinical and clinical studies [32–36]. One of the main rea-
ons for this failure is the delicate balance between the induction
f augmented immunogenicity by TLR agonists and safety concerns,
hich are often related to the generation of systemic inﬂammatory
esponses [19,37–39].
Several  groups have utilized micro- and nanocarriers, such as
irus-like particles, liposomes, and PLGA particles, to encapsulate
djuvants [40–42]. Encapsulation of adjuvants reduces systemic
xposure of adjuvant and enhances uptake by APCs. Nano-size
iruses and particles distribute rapidly to the local draining lymph
ode where they are taken up by subcapsular macrophages and2 (2014) 2882–2895 2883
dendritic  cells [41,43,44]. Antigens can also be delivered in par-
ticles to target efﬁcient uptake by APCs [36,41,45,46]. Recent
studies show that co-encapsulation of both antigen and adjuvant
in nanoparticulate carriers have synergistic effects in augmenting
immunity by targeting both antigen and adjuvant to the endosomal
compartment of APCs [36,42,46].
In this study, we evaluated the immune responses induced
by synthetic vaccine particles (SVP) carrying covalently bound
or entrapped TLR agonist co-delivered with encapsulated antigen
(either in the same or in separate nanoparticle preparations). We
hypothesized that such an approach may  provide a two-pronged
beneﬁt by enabling a focused delivery of antigen and adjuvant and
hence enhancing immunogenicity while preventing systemic expo-
sure of the TLR agonist, which can result in excessive systemic
cytokine release. Indeed, encapsulation of TLR agonist changed
the dynamics of cytokine induction in vitro and in vivo. Sys-
temic cytokine production observed with free resiquimod (R848)
was suppressed by its encapsulation within nanoparticles. At the
same time, SVP-encapsulated TLR agonists, but not free TLR ago-
nists, promoted sustained cytokine induction in the local draining
lymph node as well as a robust inﬁltration by APCs and, later,
by antigen-responsive cells. SVP-encapsulated TLR7/8 and TLR9
ligands augmented humoral and cellular immune responses to
both soluble and nanoparticle-delivered protein compared to that
observed with free adjuvants. Furthermore, this augmentation did
not require co-encapsulation of antigen and TLR agonist in the same
SVP. Collectively, these data indicate that SVPs may enable the use
of potent TLR agonists as novel adjuvants by targeting their activ-
ity to the draining lymph node and minimizing systemic exposure,
thereby reducing adjuvant-related side effects.
2. Materials and methods
2.1.  Mice
Six- to eight-week-old female C57BL/6 mice were purchased
from Charles River Laboratories (Wilmington, MA,  USA) or Taconic
(Germantown, NY, USA). All animal protocols were reviewed and
approved by IACUC in accordance with federal, state and city of
Cambridge (MA, USA) regulations and guidelines.
2.2. Cells and reagents
Fresh  murine splenocytes were cultivated in RPMI with 10% FBS
and were assayed in 96-well plates at 20,000–50,000 cells/well. Cell
lines J774 (murine macrophages), EL4 (H-2b murine thymoma),
and E.G7-OVA (EL4 cells transfected with full the length gene
encoding chicken OVA) were purchased from the ATCC (Ameri-
can Type Culture Collection, Rockville, MD, USA) and grown per
manufacturer’s recommendations. R848 was  purchased from Enzo
Life Sciences (Farmingdale, NY, USA) or Princeton Global Synthe-
sis (Bristol, PA, USA). Phosphorothioate (PS) or phosphodiester
(PO) forms of CpG-1826 (5′-TCCATGACGTTCCTGACGTT-3′) were
purchased either from Enzo Life Sciences or from Oligo Factory
(Holliston, MA,  USA). OVA was  purchased from Worthington Bio-
chemical Corporation (Lakewood, NJ, USA). Recombinant prostatic
acid phosphatase (PAP) was expressed in Escherichia coli and puri-
ﬁed by Virogen (Watertown, MA,  USA). Aluminum hydroxide gel
(alum) was  purchased from Sigma–Aldrich (St. Louis, MO, USA).
The  poly(lactide) or poly(lactide-co-glycolide) polymers (PLA or
PLGA) were purchased from Lakeshore Biomaterials (Birmingham,
AL, USA) unless otherwise speciﬁed. Poly(lactide)-bl-poly(ethylene
glycol)  monomethyl ether diblock copolymer (PLA-PEG-OMe) was
prepared according to the literature [47,48]. Dichloromethane
(CH2Cl2), acetonitrile, HPLC grade water, triethylamine (TEA), and
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riﬂuoroacetic acid (TFA) were purchased from VWR  International
Radnor, PA, USA). Dimethylsulfoxide (DMSO) was  purchased from
igma–Aldrich. Fluorescamine was purchased from Tokyo Chemi-
al Industry America (Waltham, MA,  USA). Cellgro PBS 1X (PBS) was
urchased from Mediatech, Inc. (Manassas, VA, USA). PLGA-R848
olymer was prepared by Princeton Global Synthesis. Polyvinyl
lcohol was purchased from EMD  Millipore (Billerica, MA,  USA).
.3.  SVP preparation and analysis
All of the SVP were prepared using a double emulsion
ater/oil/water system [49]. Brieﬂy, the polymers were prepared
t 10% wt/vol in CH2Cl2, and OVA was prepared at 50 mg/mL  in
BS. In formulations without OVA, we substituted the OVA aque-
us phase with PBS. Emulsiﬁcation via sonication was  performed
sing a Branson Digital Soniﬁer model 250 equipped with a model
02 C converter and a 1/8′′ tapered microtip from Branson Ultra-
onics (Danbury, CT, USA). Centrifugation was carried out using a
eckman Coulter J-30I centrifuge with a JA-30.50 rotor (Beckman
oulter, Brea, CA, USA). The primary emulsion was carried out in a
hick walled glass pressure tube with an aqueous to organic phase
atio of 1:5. Following a brief sonication step, Emprove PVA 4–88
queous solution was added to the polymer organic solution (at
 volume ratio of 3:1 PVA to organic phase), vortex mixed, and
mulsiﬁed by sonication. The resultant double emulsion was  then
ransferred into a beaker under stirring containing 70 mM phos-
hate buffer pH 8.0 at a volume ratio of 1 part double emulsion
o 7.5 parts buffer. The organic solvent (CH2Cl2) was allowed to
vaporate for 2 h under stirring, and the nanoparticles were recov-
red via centrifugation at 75,600 rcf with two wash steps. PBS was
sed for the wash solutions and the ﬁnal resuspension media. The
ashed SVP suspension was stored at −20 ◦C.
Determination of OVA loading was performed using the ﬂu-
rescamine test from Udenfriend et al. [50]. R848 and CpG
oading were each determined by SVP hydrolysis followed by
eversed-phase HPLC analysis. Brieﬂy, nanoparticle solutions were
entrifuged, and the pellets were subjected to base hydrolysis to
elease the adjuvant. R848 hydrolysis was carried out at room
emperature using concentrated ammonium hydroxide. Results
ere quantiﬁed from the absorption of R848 at 254 nm using
obile phases comprised of water/acetonitrile/TFA. For CpG analy-
is, NaOH was used at elevated temperature, with results quantiﬁed
rom the absorption of CpG at 260 nm.  The HPLC mobile phases for
pG analysis used acetonitrile/water/TEA.
The SVP concentration was determined gravimetrically. Brieﬂy,
liquots of SVP were centrifuged at 108,800 rcf to pellet out the
anoparticles. The supernatant was discarded, and the pellet was
ried (72 h, 37 ◦C, atmospheric pressure). SVP concentrations were
alculated by comparing the weight of the microtube at each of the
ollowing steps: empty, with the nanoparticle solution, with the
upernatant discarded, and then after the incubator drying step.
.4.  Vaccination
Groups of 3–10 mice were injected s.c. in the hind limb with PBS
ehicle containing SVP-formulated or free antigens and adjuvants
ither in both limbs (30 l volume per a single injection site, 60 l
otal) or in a single limb (60 l total volume). The standard SVP
njection dose was 100 g per animal (unless speciﬁed otherwise).
 single time-point injection was used in cytokine production
nd T cell induction experiments, and prime-boost regimens (2–3
mmunizations with 14 or 28-day intervals; detailed in ﬁgure leg-
nds) were used in experiments assessing antibody generation.
ntranasal inoculation in both nares (60 l total volume) was done
t a single time-point under light anesthesia.32 (2014) 2882–2895
2.5.  Determination of antibody titers by ELISA
96-Well Costar plates (Corning Inc., Corning, NY, USA) were
coated with 100 l per well of OVA protein (5 g/mL) or prostatic
acid phosphatase (PAP) protein (1 g/mL; Virogen) and incubated
overnight at 4 ◦C. Plates were washed three times with 0.05%
Tween-20 in PBS, 300 l diluent (1% casein in PBS; Thermo Fisher,
Waltham, MA,  USA) was added to each well to block non-speciﬁc
binding, and plates were incubated for at least 2 h at room tem-
perature (RT). Plates were washed as described above, and serum
samples were serially diluted 3-fold down the plate and incubated
for 2 h at RT. Two columns of standards were included on each plate
(anti-OVA monoclonal antibody, Abcam, Cambridge, MA, USA)
starting at 0.25 g/mL and diluted 3-fold down the plate. Naive
mouse serum was used as a negative control. Plates were washed
and detection antibody (either biotinylated goat anti-mouse Ig (BD
Biosciences, San Jose, CA, USA) or horseradish peroxidase (HRP)-
conjugated goat anti-mouse IgG (Abcam)) was  added to each well.
For antibody isotyping, goat anti-mouse IgG1 (Southern Biotech,
Birmingham, AL, USA) and anti-mouse IgG2c (Bethyl Laboratories,
Montgomery, TX, USA) (both HRP-conjugated) were used. Plates
were incubated in the dark for 1 h at RT and washed (three times,
with at least a 30-s soak between each wash). For plates with
biotinylated antibodies, plates were incubated for 30 min  in the
dark at RT with streptavidin–HRP (BD Biosciences) and washed
(three times, with at least a 30-s soak between each wash). TMB
substrate (BD Biosciences, San Jose, CA, USA) was added, and plates
were incubated for 10 or 15 min in the dark. The reaction was
stopped by adding stop solution (2N H2SO4) to each well, and the
OD was  measured at 450 nm with subtraction of the 570 nm reading
using a Versamax plate reader (Molecular Devices, Sunnyvale, CA,
USA). Data analysis was  performed using SoftMax Pro v5.4 (Molecu-
lar Devices). A four-parameter logistic curve-ﬁt graph was  prepared
with the serum dilution on the x-axis (log scale) and the OD value
on the y-axis (linear scale), and the half maximum value (EC50) for
each sample was determined to calculate antibody titer.
2.6.  Lymph node preparation for lymphocyte cultivation
Four days post s.c. injection with SVP or free antigen (alone or
with TLR agonist), mice were sacriﬁced, draining popliteal lymph
nodes aseptically removed and digested for 30 min at 37 ◦C in
400 U/mL collagenase type 4 (Worthington, Lakewood, NJ, USA).
Single cell suspensions were prepared by forcing digested lymph
nodes through a 70-m nylon ﬁlter membrane, then washed in
PBS containing 2% FBS and counted using a Countess® cell counter
(Life Technologies, Carlsbad, CA, USA). Lymph node derived lym-
phocytes were then seeded at 5 × 106 cells/mL in 96-well plate
(round-bottom) and cultured for an additional 4 days in RPMI-1640
supplemented with 10% (v/v) heat inactivated FBS, 10 U/mL recom-
binant human IL-2, 50 M 2-ME, and antibiotics (penicillin-G and
streptomycin sulphate, both at 100 IU/mL).
2.7.  In vitro cytotoxicity
OVA  speciﬁc cytolytic activity in vitro was determined via
lactate dehydrogenase (LDH) release CytoTox96 Assay (Promega,
Madison, WI,  USA) according to manufacturer’s recommenda-
tions. Brieﬂy, effector lymphocytes were cultured in limiting
dilution either alone or with appropriate target cells, EL4 or
E.G7-OVA at 37 ◦C for 18 h. CTL activity was assessed by mea-
suring relative LDH with maximum and spontaneous release
values measured against LDH within supernatants of effector
target combinations. Speciﬁc lysis was  calculated as follows:
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Fig. 1. Adjuvant encapsulation in nanoparticles (SVP) results in suppressed TNF induction in murine cells in vitro. SVP containing TLR7/8 agonist R848 (A, B) or TLR9 agonists
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Fig. 2. Nanoparticle encapsulation of both antigen and TLR7/8 agonist (R848),
whether  co-encapsulated or in separate particles, results in a higher humoral
immune  response than utilization of free TLR7/8 agonist and/or free antigen. Groups
of 5–10 mice were immunized (3 times, 4-week intervals, s.c., hind limb) withO-CpG 1826 (C) or PS-CpG1826 (D) were added to J774 cells (A, C) or fresh mous
NF-  in culture supernatants was measured 6 h (splenocytes) or 16 h (J774) after 
ice are shown.
ercent speciﬁc lysis (%) = 100 × [(experimental − T cell sponta-
eous)/(target max  − target spontaneous)].
.8.  In vivo cytotoxicity
OVA-speciﬁc cytolytic activity in vivo was determined as
escribed [51] at 6 days after a single immunization. Brieﬂy, spleno-
ytes from syngeneic naïve mice were labeled with either 0.5 M,
r 5 M CFSE, resulting in CFSElow and CFSEhigh cell populations,
orrespondingly. CFSEhigh cells were incubated with 1 g/mL of
IINFEKL peptide at 37 ◦C for 1 h, while CFSElow cells were incu-
ated in medium alone. Both populations were mixed in a 1:1 ratio
nd injected into immunized or control animals (i.v., 2.0 × 107 cells
otal). After 18-h incubation, spleens were harvested, processed
nd analyzed by ﬂow cytometry. Speciﬁc cytotoxicity was cal-
ulated based on a control ratio of recovery (RR) in naïve mice:
percentage of CFSElow cells)/(percentage of CFSEhigh cells). Percent
peciﬁc lysis (%) = 100 × [1 − (RR of cells from naive mice/RR of cells
rom immunized mice) or 100 × [1 − (RRnaive/RRimm)].
.9.  Determination of cytokine concentration in sera and culture
upernatants
Free  or SVP-encapsulated TLR agonists were serially diluted
n tissue culture medium and added to J774 cells or fresh
urine splenocytes. Culture supernatants were collected after
–48 h and assayed for TNF- and IL-6 by ELISA (BD Biosciences,
A, USA). Local cytokine secretion was determined in culture
various combinations of SVP-OVA or free OVA and/or SVP-R848 or free R848, as
indicated. The same dose of OVA (5.6 g) was used in all experimental groups and
the same dose of R848 (6.8 g) was used in all groups in which R848 was  admin-
istered.  Antibody generation was measured by ELISA at the indicated time-points
and  is presented as log10 of EC50 with standard deviations.
2886 P.O. Ilyinskii et al. / Vaccine 32 (2014) 2882–2895
Fig. 3. Nanoparticle encapsulation of both antigen and TLR7/8 agonist (adjuvant) results in higher local and systemic cellular immune responses than utilization of free
antigen or adjuvant. A – total draining lymph node (LN) cell count, B – SIINFEKL-positive CD8+ T cells in draining lymph node (absolute numbers – gray bars, left Y-axis;
percentage of total CD8+ T cells – hatched bars, right Y-axis), C – ﬂow cytometric analysis of SIINFEKL-positive CD8+ T cells ex vivo, D – ﬂow cytometric analysis of SIINFEKL-
positive CD8+ T cells after in vitro expansion, E – in vitro cytotoxic activity of LN-derived cells against OVA-expressing target cells, and F – in vivo cytotoxicity against
SIINFEKL-pulsed syngeneic splenocytes. Groups of 3–6 mice were injected (s.c., hind limb) either with SVP-encapsulated or free OVA and/or R848 in combinations indicated.
At  4 days after injection, total cells in the popliteal LNs were isolated and counted (A). LN cells were then stained for surface markers either immediately (B, C) or after 4
days  of in vitro expansion on IL-2 without feeder/stimulator cells (D). The percentage of antigen-speciﬁc CTL stained with SIINFEKL-MHC class I pentamer and anti-CD8
antibody was assessed by ﬂow cytometry (indicated in boxes in C and D; samples from two representative animals shown). In vitro cytotoxic activity was assessed after
in  vitro expansion of LN cells, as described. The difference between speciﬁc (E.G7-OVA transfected targets cells) and non-speciﬁc (EL-4 parental cells) cytotoxicity is shown
(E).  The amount of free or SVP-encapsulated OVA and R848 in g/injection dose is indicated in parentheses. The effector-to-target ratio (E:T ratio) is depicted in the x-axis.
In  vivo CTL activity (F) was  assessed in mice (n = 2–4/group) injected s.c. with SVP-encapsulated or free OVA either alone or with free or SVP-encapsulated R848, as indicated.
The  total dose of OVA was  the same across all treatment groups, and the total dose of R848 was  the same for all groups receiving R848. Speciﬁc in vivo cytotoxicity was
determined as described in Section 2 at 6 days post-immunization. All experiments presented in this ﬁgure were run 2–3 times.
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Fig. 4. Local cytokines are induced by SVP-encapsulated, but not free, TLR7/8 agonist R848. Mice were injected s.c. in both hind limbs with either SVP-OVA-R848, SVP-OVA,
or  SVP-OVA admixed with free R848. At the times indicated, popliteal LNs were taken and incubated in vitro overnight. Culture supernatants were collected and analyzed
for  the presence of speciﬁc cytokines by ELISA. A – IFN-, B – RANTES, C – IL-12(p40), D – IL-1. Average of four LNs per time-point is shown.
Table 1
Local  lymphadenopathy induction by administration of SVP-encapsulated but not
free TLR7/8 agonist.
Day SVP-R848 SVP (no adjuvant) SVP (no adjuvant) + R848
0 1.00 1.00 1.00
1  1.50 1.36 1.08
4  3.19 1.53 1.03
7  8.06 1.53 0.84
Mice were injected subcutaneously (hind limb) with SVP-R848, SVP (no adjuvant)
o
t
(
s
(
v
o
p
F
Table 2
Local  lymphadenopathy after administration of SVP-encapsulated TLR7/8 agonist
and antigen in naïve vs. pre-immunized mice.
Day SVP-R848, total cells in LN
Naïve mice Immune mice
0 1.00 1.00
3 4.33 10.14
8 8.04 9.86
14 5.36 6.93
21 4.14 6.60
Naive or previously immunized mice were injected with SVP-R848 with co-
T
L
M
n
t
fr  SVP (no adjuvant) admixed with free R848. Popliteal LNs were taken at various
imes  as indicated. Total lymph node cells (normalized to day 0 values) in all groups
average of 3 mice per time-point) are shown.
upernatants after brief in vitro incubation of draining lymph nodes
LNs) from immunized animals. Brieﬂy, popliteal LN were har-
ested at different intervals after injection of SVP, free TLR agonist,
r PBS and were incubated individually (complete LN, without
rocessing) for 16 h in 300 l of supplemented RPMI-1640 with
BS as described above. Culture supernatants were then assayed
able 3
ocal  lymphadenopathy and immune cell population expansion after administration of S
Day Total cells CD11c+ B220−
(mDC)
CD11c+ B220+
(pDC)
B220+ CD11c−
(B cells)
F4/80
(Mø)
0 1.00 1.00 1.00 1.00 1.000
1  1.50 3.15 1.36 0.98 1.97 
4  3.19 6.50 8.14 3.56 1.16 
7  8.06 7.00 7.77 11.09 2.51 
ice were injected s.c. (hind limb) with SVP-R848, SVP (no adjuvant), or SVP (no adjuvant
ode  cells were counted, stained for various surface markers, as indicated, and analyzed
able  are from SVP-R848 injected mice. No marked variation in LN cell populations was  
ree  R848 (not shown). Mø  – macrophages, mDC  and pDC – myeloid and plasmacytoid DCencapsulated  antigen (hind limb, s.c.). Popliteal LNs  were taken at various times
as  indicated. Total lymph node cell counts (normalized to day 0 values) in all groups
(average of 3 mice per time-point) are shown.for murine cytokines by ELISA using speciﬁc kits (BD Biosciences) or
by multiplex ELISA biomarker assays (Aushon BioSystems, Billerica,
MA, USA). Cytokine levels determined in the cultures from LNs of
PBS-immunized animals were used as the initial time-point (0 h).
VP-encapsulated TLR7/8 agonist.
+ GR1− F4/80− GR1+
(Gran)
CD3+ (T cells) CD3− CD49b+
(NK)
CD3+ CD49b+
(NKT)
 1.00 1.00 1.00 1.00
3.52 1.52 1.03 0.62
14.20 2.54 9.64 6.72
18.43 4.39 8.57 8.25
) admixed with free R848. Popliteal LNs were taken at times indicated. Total lymph
 by ﬂow cytometry. Cell numbers were normalized to day 0 values. Data shown in
seen in mice injected with “no adjuvant”-SVP or “no adjuvant”-SVP admixed with
, Gran – granulocytes, NKT – NK T cells.
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Fig. 5. Focused local cytokine induction after a single-site injection with SVP-
encapsulated,  but not free, TLR7/8 agonist R848. Mice were injected s.c. in a single
hind limb with either SVP-R848 or free R848. At the times indicated, popliteal LNs
from the injection side (ipsilateral, I) and from the opposite side (contralateral, C)888 P.O. Ilyinskii et al. / Va
imilarly, systemic cytokine levels in pooled or individual serum
amples drawn from vaccinated animals via terminal bleeds at dif-
erent time intervals after inoculation were measured by ELISA.
ytokine levels from the sera of PBS-immunized animals were con-
idered as the initial time-point (0 h). All experiments on cytokine
easurement in vivo were run two or three times yielding similar
esults for each experimental group.
.10. Flow cytometry
At  different time-points after injection with SVP, free TLR ago-
ist or PBS, mice were sacriﬁced, draining popliteal lymph nodes
arvested and digested for 30 min  at 37 ◦C in 400 U/mL collagenase
ype 4 (Worthington, Lakewood, NJ, USA). Single cell suspensions
ere prepared by forcing digested lymph nodes through a 70-m
ylon ﬁlter membrane, then washed in PBS containing 2% FBS and
ounted using a Countess® cell counter (Life Technologies, Carls-
ad, CA, USA). Cells were stained pairwise with antibodies against
he following mouse surface cell molecules: B220 and CD11c, CD3
nd CD49b, F4/80 and Gr1 (BD Biosciences, CA, USA). The gating
ogic was as follows: plasmacytoid dendritic cells (CD11c+, B220+),
yeloid dendritic cells (CD11c+, B220−), B cells (CD11c−, B220+),
ranulocytes (GR-1+, F4/80−), macrophages (GR-1−, F4/80+), NK T
ells (CD49b+, CD3+), NK cells (CD49b+, CD3−), and T cells (CD49b−,
D3+). Similarly, SIINFEKL-loaded pentamers (Proimmune, Oxford,
K), were used along with anti-mouse CD8 and CD19 (to gate out
on-speciﬁc pentamer binding). Cell samples were then washed
nd immediately analyzed by ﬂow cytometry. Data were analyzed
ith FlowJo software (Tree Star Inc., Ashland, OR, USA).
.  Results
.1. Nanoparticle encapsulation of TLR agonists changes the
attern  of inﬂammatory cytokine induction in vitro
TLR7/8 (R848) and TLR9 (CpG ODN 1826; mouse-speciﬁc B-
ype CpG ODN) agonists were encapsulated in synthetic polymer
anoparticles and tested for their ability to induce cytokines in
itro. R848 was chemically conjugated to PLGA and used for SVP for-
ulation as PLGA-R848, and CpG ODN was passively entrapped into
VP as described in Section 2. Natural oligonucleotide sequences
ontain a phosphodiester (PO) backbone, which is susceptible to
apid hydrolytic cleavage by nucleases in vivo. Nuclease-resistant
pG sequences with a phosphorothioate (PS) backbone have been
hown to have superior activity to PO-CpG in vivo. Both PS and PO
orms of the immunostimulatory CpG ODN 1826 sequence (PS-CpG
826 and PO-CpG 1826) were evaluated. SVP-encapsulated R848
nduced lower levels of TNF- from splenocytes and especially from
urine macrophages than identical amounts of free R848 (Fig. 1A
nd B). Similar proﬁles were seen when PS-CpG 1826 and PO-CpG
826 sequences were tested in free or SVP-encapsulated form. Not
urprisingly, PO-CpG 1826 was a less potent inducer of TNF- pro-
uction than PS-CpG 1826, with its SVP-encapsulated form being
early inactive, even in the more sensitive J774 cells (Fig. 1C and
). IL-6 production in vitro followed the same pattern as TNF-
data not shown). However, a static in vitro system does not cap-
ure potential differences in biodistribution and pharmacokinetics
f free adjuvant versus nanoparticle-encapsulated adjuvant that
re expected in vivo.
.2.  Nanoparticle encapsulation of TLR7/8 agonist increases its
djuvant  activity while antigen encapsulation increases
mmunogenicity in vivo
The  adjuvant activity of nanoparticle-encapsulated R848 (SVP-
848) was assessed in vivo in immunogenicity studies withwere collected and incubated in vitro overnight. Culture supernatants were ana-
lyzed for the presence of speciﬁc cytokines by ELISA. A – IFN-, B – IL-12(p40), C –
IL-1. Average of two mice per time-point is shown.
a model antigen, OVA (Fig. 2). The potency of free and SVP-
encapsulated R848 to induce antibodies to OVA was compared
in a standard prime-boost immunization regimen. Both free and
nanoparticle-encapsulated forms of OVA were tested (OVA and
SVP-OVA, respectively). Additionally, R848 and OVA were either
co-encapsulated in the same particle (SVP-OVA-R848) or were
admixed as separate particles (SVP-R848 and SVP-OVA). When
admixed with soluble OVA, SVP-R848 resulted in nearly a 10-fold
P.O. Ilyinskii et al. / Vaccine 32 (2014) 2882–2895 2889
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Fig. 6. Strong systemic cytokine induction after injection of free, but not SVP-encapsulated TLR7/8 agonist R848. Mice were injected s.c. with either SVP-OVA-R848, SVP-OVA
or  SVP-OVA admixed with free R848 and bled at times indicated. The same amount of free or SVP-encapsulated R848 was used for each group (6.8 g). Serum samples were
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Sollected at the times indicated and analyzed for individual cytokines by ELISA. Ave
NF-,  B – IL-6, C – RANTES, D – IP-10, E – IL-12(p40), F – MCP-1.
ncrease in immunogenicity compared to free R848 after two  or
hree injections (Fig. 2). SVP-R848 exceeded the potency of alum,
n adjuvant in numerous commercially approved vaccines, by an
ven higher margin (antibody titer EC50 values for animals immu-
ized with OVA in alum were below the cut-off level for the assay).
otably, the presentation of OVA by SVP also resulted in a marked
ncrease of antibody response (by at least 2–3 orders of magni-
ude) compared to free OVA with or without alum. Addition of
ree R848 to SVP-OVA further increased immunogenicity, especially
fter one or two injections, but its effect was not pronounced after
he third vaccination. Free R848 was also inferior to encapsulated
848 whether it was co-encapsulated with OVA (SVP-OVA-R848)
r present in a separate particle (SVP-OVA + SVP-R848). On average,
o-encapsulation of OVA and R848 led to a 0.5-log increase in anti-
ody titer compared to utilization of free R848, while admixing of
VP-OVA with SVP-R848 was more potent in antibody generationytokine concentration is shown (three samples per group per each time-point). A –
than  addition of a free R848 to SVP-OVA by an order of magnitude
(Fig. 2). While addition of free R848 to SVP-OVA led to a clear Th1
shift in antibody response after two  injections (IgG1:IgG2c ratios
of 0.28 vs. 3.13 at day 40 for SVP-OVA + R848 and SVP-OVA, corre-
spondingly), the difference was  even more pronounced if R848 was
SVP-encapsulated (IgG1:IgG2c ratios of 0.08 for SVP-OVA-R848 and
0.11 for SVP-OVA + SVP-R848).
Similarly, nanoparticle-encapsulated OVA and R848 induced
strong local and systemic cellular immune responses (Fig. 3). Injec-
tion of nanoparticle-encapsulated R848 led to a signiﬁcant inﬂux
of cells into draining lymph nodes (LN) even after a single inocula-
tion (Fig. 3A). Moreover, utilization of encapsulated R848 (whether
with free or co-encapsulated OVA) elevated both the percentage
and absolute quantities of locally induced antigen-speciﬁc CD8+ T
cells, as assessed by reactivity with MHC  class I pentamers con-
taining the dominant ovalbumin epitope, SIINFEKL (Fig. 3B and C).
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Fig. 7. Systemic cytokine induction after intranasal inoculation of free, but not SVP-encapsulated TLR7/8 agonist R848. Mice were inoculated intranasally with either SVP-
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RVA-R848, SVP-OVA, or SVP-OVA admixed with free R848 and bled at times indicat
erum  samples were collected at the times indicated and analyzed for individual cy
ach  time-point). A – TNF-, B – IL-6, C – IL-12(p40), D – MCP-1.
ells induced by co-encapsulated R848 and OVA exhibited a higher
roliferative potential than when either free R848 or free OVA was
tilized, as evidenced by in vitro expansion of OVA-speciﬁc CD8+
 cells (Fig. 3D) and their cytotoxic activity (Fig. 3E). The in vivo
ytotoxic activity was assessed at 6 days after a single injection of
anoparticle-encapsulated or free OVA in the presence or absence
f free or nanoparticle-encapsulated R848. SIINFEKL-pulsed syn-
eneic target cells were eliminated efﬁciently in vivo only if both
VA and R848 were delivered in encapsulated form (Fig. 3F). The
evel of in vivo cytotoxic activity was maintained for several days
fter a single injection (data not shown). The admix of nanoparticle-
ncapsulated OVA with free R848 or the admix of free OVA with
anoparticle-encapsulated R848 induced poor in vivo cytotoxic
ctivity (Fig. 3F).
.3.  Rapid inﬁltration of draining lymph nodes by innate and
daptive  immune cells upon injection of
anoparticle-encapsulated R848
R848-bearing nanoparticles induced a profound increase in cel-
ularity within the draining lymph nodes at 4 days after a single
noculation (Fig. 3A). Further analysis of cellularity within the
raining lymph nodes after s.c. injection showed that LN inﬁltration
tarts as early as 1 day after inoculation, reaches a peak at 7–8 days,
nd is maintained for at least 3 weeks (Tables 1 and 2). The increase
n lymph node cellularity was even more rapid and pronounced in
ice that were previously immunized with SVP (10-fold increasen the popliteal LN cell count at 1 day after inoculation, Table 2).
o signiﬁcant cell inﬁltration of the draining lymph node was seen
f SVP lacking R848 were used either alone or admixed with free
848 (Table 1).e same amount of free or SVP-encapsulated R848 was used for each group (3.8 g).
s by ELISA. Average cytokine concentration is shown (three samples per group per
A detailed analysis of intranodal cell populations after SVP-R848
injection showed a rapid increase in the number of innate immune
cells, such as granulocytes and myeloid DC, in the draining LN, with
their numbers increasing 3-fold within 24 h after a single injec-
tion (Table 3). There was  also an early elevation in macrophage
cell numbers in the draining lymph node, while increases in other
APC subtypes (plasmacytoid DC and B cells) were observed at a
slightly later time-point. Interestingly, among the populations ana-
lyzed, only effector cells of the adaptive immune response (T and B
cells) showed a continued expansion from day 4 to day 7 (Table 3).
3.4. Nanoparticle encapsulation of TLR7/8 agonist induces strong
local  cytokine production
Strong  local immune activation by nanoparticle-encapsulated
R848  was  further manifested by cytokine production in the drain-
ing LN milieu (Figs. 4 and 5). At 4 h after subcutaneous injection,
high levels of IFN-, RANTES, IL-12(p40) and IL-1 were secreted
by LNs from animals injected with SVP-OVA-R848, while the pro-
duction of these cytokines by LNs from mice injected with free R848
was close to the background level (Fig. 4). In particular, the amount
of IFN- secreted by LNs from mice injected with SVP-OVA-R848 at
4 h was  more than 100-fold higher than that from the LNs of mice
injected with SVP-OVA and an equal amount of free R848 (Fig. 4A),
while RANTES was elevated more than 27-fold (Fig. 4B). Produc-
tion of all of these cytokines in the LN was  maintained for at least
72 h after injection of SVP-OVA-R848, with levels of IL-12(p40) and
IL-1 remaining nearly stable (Fig. 4C and D), and levels of IFN-
and RANTES, while decreasing, remaining 4- to 20-fold higher than
the background. In contrast, inoculation of free R848 led to only a
modest increase of local cytokine production at 4 h, which returned
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Fig. 8. Higher humoral immunogenicity of SVP-encapsulated antigen coupled with
free TLR9 agonist PS-CpG or with SVP-encapsulated TLR9 agonist PO-CpG. Mice
(5/group) were immunized (s.c., hind limb) with the indicated SVP or combina-
tions  of free antigen and PS-CpG 1826. Antibody titers were determined at times
indicated.  Mice were immunized either two  (A, C) or three (B) times with 2-week
intervals between immunizations. OVA (A, B) and prostatic acid phosphatase (PAP)
(C) proteins were evaluated as test antigens, either in free form or encapsulated in
SVP. In Panel B, the total dose of both free OVA and free PS-CpG 1826 was  ﬁve times
greater than that administered in the SVP-treated groups. In Panel C, the amount
of  free PAP used was 50 times higher than that of SVP-encapsulated PAP, and theP.O. Ilyinskii et al. / Va
o background levels by 24 h after administration. Levels of IP-10
nd MCP-1 in LNs from SVP-OVA-R848-injected animals were also
levated in a similar fashion (data not shown).
The striking difference in local cytokine production after admin-
stration of nanoparticle-encapsulated versus free R848 (Fig. 4) was
lso evident by comparing cytokine production in the ipsilateral
raining lymph node versus the contralateral lymph node after
njection in a single hind limb (Fig. 5A and B). The sustained expres-
ion of IFN-, IL-12(p40), and IL-1 was seen in the ipsilateral LN
t 4–48 h after injection of SVP-R848, but not in the contralateral
ymph node. In contrast, free R848 induced a modest elevation of
L-12(p40) and IFN- in both the ipsilateral and contralateral lymph
odes (Fig. 5B). The level of IFN- observed in the ipsilateral lymph
ode following injection of free R848 was 50-fold lower than that
nduced by SVP-R848 (Fig. 5A). No induction of IL-1 by free R848
as seen (Fig. 5C).
.5.  Nanoparticle encapsulation of TLR7/8 agonist R848
ttenuates the production of systemic inﬂammatory cytokines
While  nanoparticle encapsulation of R848 enhanced immuno-
enicity and local induction of immune cytokines, the production
f systemic inﬂammatory cytokines by SVP-R848 was markedly
uppressed compared to that observed with free R848 after either
ubcutaneous or intranasal inoculation (Figs. 6 and 7, respec-
ively). In particular, 4 h after subcutaneous inoculation, serum
oncentrations of early inﬂammatory cytokines TNF- and IL-6
ere 50–200 times higher if free R848 was used (Fig. 6A and B).
erum cytokine levels were similar in animals inoculated with SVP-
VA with or without encapsulated R848. Similar differences were
bserved with systemic production of RANTES (Fig. 6C). SVP-OVA-
848 induced modest levels of IP-10, IL-12(p40), and MCP-1, which
ere approximately 5–10 times lower than that observed after
njection of SVP-OVA admixed with free R848 (Fig. 6D–F).
Patterns  of systemic cytokine expression proﬁles after
ntranasal delivery of either free or encapsulated R848 (Fig. 7)
ere similar to those seen after s.c. delivery. Serum TNF- and
CP-1 were only weakly induced by SVP-R848, with levels 10- to
00-fold lower than those induced by free R848 (Fig. 7A and D),
hile levels of IL-6 and IL-12(p40) induction were 5 times lower
Fig. 7B and C).
.6.  Nanoparticle encapsulation of TLR9 agonist permits effective
tilization  of immunostimulatory phosphodiester CpG ODNs
n  vivo
We  next assessed the adjuvant activity of a nanoparticle-
ncapsulated TLR9 agonist, CpG-1826, in immunogenicity studies
ith a model antigen, OVA. It is known that a PO form of CpG is
ubject to rapid degradation by nucleases [36,46] and therefore the
ackbone-modiﬁed PS form is usually employed in vivo. We  rea-
oned that nanoparticle encapsulation may  protect the PO form
rom premature degradation and enable use of PO-CpG in vivo.
o-administration of nanoparticle-encapsulated OVA and PO-CpG
826 induced antibody titers comparable to that obtained with
anoparticle-encapsulated OVA admixed with the same dose of
ree PS-CpG 1826 (Fig. 8A). Animals immunized with the same
oses of free OVA admixed with free PS-CpG 1826 exhibited 20-
o 40-fold lower antibody titers (Fig. 8A). Increasing the dose of
ree OVA and free PS-CpG 1826 did not increase the antibody
iters compared to SVP-encapsulated OVA and PO-CpG (Fig. 8B).
hen another antigen, prostatic acid phosphatase (PAP), wasvaluated, PS-CpG 1826 was inferior by nearly two orders of magni-
ude in antibody induction compared to nanoparticle-encapsulated
AP and PO-CpG 1826 (Fig. 8C). Nanoparticle entrapment of PS-
pG 1826 did not lead to higher immunogenicity compared toamount of free PS-1826 was  two times higher than used in SVP-encapsulated form
(C). No adjuvant effect of free PO-1826 was  detected (data not shown).
entrapped PO-CpG 1826, while utilization of free PO-CpG 1826
resulted in no augmentation of immunogenicity (data not shown).
When nanoparticle-encapsulated OVA and PO-CpG 1826 were
compared to free OVA and free PS-CpG 1826 in their ability to
induce speciﬁc CTLs in vivo, the combination of the former was
more effective even if 10 times more free OVA and 5 times more
free PS-CpG 1826 were used (Fig. 9).
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Fig. 9. Nanoparticle encapsulation of both antigen and TLR9 agonist PO-CpG (adjuvant) results in a higher local cellular immune response than utilization of free antigen and
adjuvant.  Groups of 2–3 mice were injected (s.c., hind limb, once or twice with 2-wk interval) with a combination of SVP-encapsulated OVA and SVP-encapsulated PO-CpG
1826, free OVA admixed with free PS-CpG 1826, or PBS as indicated. The amount of free OVA (50 g) was ten times higher and the amount of free PS-CpG 1826 (20 g)
was  ﬁve times higher than that present within SVP (5 and 4 g, respectively). Tissues were taken at 5 days after the last immunization and restimulated in vitro for 7 days
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No signiﬁcant induction of inﬂammatory cytokines (TNF-, IL-
) in serum was seen when free or encapsulated PO and PS forms of
pG-1826 were tested, while free PS-CpG 1826 induced the produc-
ion of IL-12(p40) to the same levels as nanoparticle-encapsulated
O-CpG  1826 (Table 4). Nanoparticle entrapment of PS-CpG 1826
ed to elevated and sustained local production of IFN-, IL-12(p40),
nd IL-1, which exceeded that of free PS-CpG 1826 (used in 10-fold
xcess, Fig. 10), closely paralleling results seen when free and SVP-
ncapsulated R848 were compared (Fig. 7). No cytokine induction
rom contralateral LN was observed after SVP-PS-CpG inoculation
Fig. 10).
.  Discussion
TLR7/8 and TLR9 agonists have shown great promise as
mmunomodulating therapeutic agents [52–61; reviewed in 36]
nd as adjuvants for DNA- [62] and protein-based vaccines [63–67].
oth R848 and CpG ODNs were seen as attractive candidates for sys-
emic use in a variety of settings [see summaries in 12,31,36,40,68]
ue to TLR7/8 and TLR9 distribution in immune cells and resulting
able 4
ystemic cytokine induction after subcutaneous administration of SVP-
ncapsulated  or free TLR9 agonist.
Cytokine peak concentration (pg/mL)
Mice injected with TNF- IL-6 IL-12(p40)
SVP-OVA 1.4 67.2 43.9
SVP-OVA + SVP-PO-CpG 1826 11.2 105.2 569.4
SVP-OVA + PO-CpG 1826 2.2 79.6 44.0
SVP-OVA + PS-CpG 1826 12.8 58.7 448.0
ice were injected subcutaneously (hind limb) with either SVP-OVA alone or com-
ined with SVP-PO-CpG 1826, free PO-CpG 1826, or free PS-CpG 1826 and bled at
.5, 1, 1.5, and 3 h after injection. Peak average cytokine concentration in serum is
hown (three samples per group for each time-point).odies and analyzed by ﬂow cytometry. Top row – popliteal LN cultures (initiated 5
er prime-boost immunization). Representative ﬂow cytometry dot plots from two
at are speciﬁc for the OVA SIINFEKL peptide (percent share of CD8+CD19− cells).
ability of these compounds to speciﬁcally activate APCs (i.e.,
dendritic cell, monocyte/macrophage, and B cell populations).
However, broad use of TLR7/8 and 9 agonists as parenteral drugs
and adjuvants has been limited due to systemic toxicity [13,69],
which is directly related to systemic cytokine release [70]. We
hypothesized that encapsulation of a TLR agonist into a nanopar-
ticle carrier may  attenuate systemic cytokine induction and thus
enable its use as a parenterally administered adjuvant. Nanopar-
ticle delivery of TLR7/8 or TLR9 agonists would have multiple
beneﬁts, including (1) minimizing systemic exposure of the TLR
agonist, (2) delivering of adjuvant to lymph nodes via direct ﬂow
of nanoparticles through draining lymphatics [43,44], (3) promot-
ing uptake into endosomal vesicles of APC, where TLR7, 8, and 9
are expressed, and (4) providing a sustained release of the TLR
agonist from a nanocarrier rather than a bolus delivery. Moreover,
nanoparticle encapsulation of both antigen and adjuvant may  have
a synergistic beneﬁt by enabling co-delivery of both antigen and
adjuvant to APCs as demonstrated earlier for microparticle delivery
vehicles [40,46].
R848  is a highly potent TLR7/8 agonist that rapidly distributes
throughout the body and exhibits a short half-life [12]. While
imiquimod, an analog of R848 which is 100-fold less potent, is
licensed as a topical drug for genital warts, actinic keratosis, and
basal cell carcinoma [31], clinical development of R848 as a topi-
cal drug and as an orally-delivered drug was discontinued due to
its narrow therapeutic window related to its short in vivo half-life
and systemic side-effects. Our results demonstrate that encapsulat-
ing R848 may  greatly increase its therapeutic window. Free R848
administered s.c. induced serum TNF- and IL-6 levels that were
50- to 200-fold higher than that observed with SVP-encapsulated
R848. The systemic production of TNF-, IL-6, and RANTES was  sup-
pressed in SVP-R848-injected animals to background levels, while
systemic induction of IP-10 and MCP-1 was also greatly attenu-
ated. The reduction in systemic cytokine production is likely due to
delivery of nanoparticles to the local draining lymph, direct uptake
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reactions. Co-encapsulation of antigen has the added beneﬁt of co-er  group per time-point is shown.
y APCs, and sustained release of R848 over time. Consistent with
his hypothesis, we observed a strong and sustained local immune
ctivation following subcutaneous administration of SVP-R848, as
videnced by cellular inﬁltration of the draining LN by APC followed
y effector cells, leading to prolonged local production of IFN-,
L-12(p40) and IL-1. In contrast, only low levels of LN cellular
nﬁltration and local cytokine production were seen upon adminis-
ration of free TLR7/8 agonist. Notably, SVP encapsulation of R848
ed to a strong induction of cellular immune responses (both local
nd systemic) even after a single immunization, while free R848
as nearly inactive.2 (2014) 2882–2895 2893
Our results conﬁrm and advance the recent ﬁndings of Tacken
et al. who  reported that nanoparticle encapsulation of TLR3 and
7/8 agonists attenuated the serum cytokine storm and enhanced
immunogenicity [71]. In this case, R848 was passively entrapped
within the nanoparticle and required antibody-mediated DC tar-
geting for delivery. The reduction in cytokine storm (measured
at a single time-point) was  not as pronounced as observed in the
present study with the SVP-based platform, even though we  used
20-fold more R848 [71]. This difference may  be due to our use of SVP
that contained R848 covalently linked to the PLGA polymer with an
acid-labile bond, a design intended to constrain R848 release to the
acidic environment within the endosome.
SVP encapsulation of a TLR9 agonist, CpG-1826, also provided
signiﬁcant beneﬁt. CpG-1826 belongs to type B CpG, capable of
activating B cells and inducing the production of proinﬂammatory
cytokines [14,72,73]. CpG-1826 encapsulation within SVP provided
for higher local cytokine production and, when co-delivered with
encapsulated antigen, resulted in higher immune responses than
antigen admixed with free CpG-1826. Unmodiﬁed CpG contains a
nuclease-labile phophodiester backbone (PO-CpG) which is known
to be rapidly degraded in vivo, thus parenterally administered
free CpG must be modiﬁed to contain a nuclease resistant phos-
phorothioate backbone (PS-CpG) to be active in vivo. Importantly,
SVP encapsulation enabled utilization of the non-phosphorothioate
form of CpG (i.e., PO-CpG) with the same efﬁciency as PS-CpG.
The use of PO-CpG in SVPs may  further reduce the potential for
systemic immune activation, as any PO-CpG that leaks out of the
nanoparticles will be rapidly degraded.
Nanoparticle encapsulation of both antigen and adjuvant may
have a synergistic beneﬁt by enabling co-delivery of both anti-
gen and adjuvant to APC. The SVP technology allows for either
covalent or non-covalent entrapment of a TLR agonist as well as
covalent and non-covalent presentation of antigen on the surface
or within the nanoparticle. The SVPs are designed to release their
payload in the low pH environment of the endolysosomal compart-
ment of APC, which contains TLR7, 8, and 9 as well as MHC class II
molecules. The sustained and concomitant release of antigen and
adjuvant from SVPs could also contribute to more potent immune
responses and better memory cell generation. Our data show that
adjuvant and antigen can be delivered in separate nanoparticles.
The ability to utilize independently formulated antigen- and TLR-
agonist-carrying nanoparticles may  be advantageous for modular
and ﬂexible vaccine design. For example, a two particle approach
can provide ﬂexibility in dosing to optimize the ratio of adjuvant-
to-antigen for a particular application.
While vaccines have been an effective and cost-efﬁcient health
care intervention for the prophylaxis of many infectious pathogens,
new vaccine technology and more potent adjuvants may  be
required to develop effective therapeutic vaccines for chronic infec-
tions, intracellular pathogens, and non-infectious diseases, such
as cancer. The immune system is keyed to respond to particu-
late antigens, such as viruses and bacteria. Synthetic nanoparticles
can mimic  key elements of viral particles by co-delivering antigen
with strong TLR agonists and effectively induce robust cellu-
lar and humoral immunity. Finally, one can envision that other
immunomodulatory agents could be incorporated into SVPs to fur-
ther ﬁne-tune the immune response by targeting speciﬁc subsets
of immune cells, such as CD8 T cells, Th1 cells, Th2 cells, Tfh, Th17
cells, T regulatory cells, B cells, and NK T cells.
Collectively, the data reported here suggest an approach to uti-
lize TLR agonists as parenterally administered vaccine adjuvants
in a clinical setting while minimizing the risk of systemic adversedelivery of adjuvant and antigen directly to APCs. The SVP approach
is currently being evaluated in pre-clinical studies such as cancer
and chronic infections, where traditional adjuvants are inadequate,
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